Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A compound of Formula I or a pharmaceutically acceptable salt thereof:



I

wherein

R^1 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^3 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, alkylamino, dialkylamino, and C_{3-6}heterocycloalkyl; and

R^4 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, and C_{3-6}cycloalkyl-C_{1-4}alkyl.

2. (original) A compound as claimed in claim 1, wherein

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{4-6}cycloalkenyl-C_{1-4}alkyl and C_{3-6}heterocycloalkyl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{4-6}cycloalkenyl-C_{1-4}alkyl and C_{3-6}heterocycloalkyl-C_{1-4}alkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy and amino;

R^2 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, and C_{4-6}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, and C_{4-6}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy and hydroxy;

R^3 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, methoxy, ethoxy, hydroxy, amino, methylamino, dimethylamino, and C_{3-6}heterocycloalkyl; and

R^4 is selected from –H and C_{1-3}alkyl.

3. (original) A compound as claimed in claim 1,

R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexyl-methyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, tetrahydropyranyl-methyl, tetrahydropyranyl-ethyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdinyl-methyl;

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl,1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

R^3 is selected from –H, C_{1-6}alkyl, and C_{1-6}acyl, wherein said C_{1-6}alkyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, methoxy, hydroxy, amino, methylamino, dimethylamino, pyrrolidinyl, and morpholinyl; and

R^4 is selected from –H and methyl.

4. (original) A compound as claimed in claim 1, wherein

R^1 is selected from cyclohexyl-methyl, cyclopentyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexy-methyl and tetrahydropyranyl-methyl;

R^2 is t-butyl and 1,1-difluoroethyl;

R^3 is selected from –H, methyl, ethyl, propyl, 2-propyl, 2-hydroxyethyl, 2-methoxyethyl, formyl, acetyl, ethylcarbonyl, 2-propylcarbonyl, t-butylcarbonyl, uriedo, N-isopropyl-ureido, 2-amino-acetyl, 2-methylamino-acetyl, 2-dimethylamino-acetyl, 2-acetyloxy-acetyl, 2-hydroxy-acetyl, 2-bromo-acetyl, 2-(morpholin-1-yl)-acetyl, and 2-(pyrrolindin-1-yl)-acetyl; and

R^4 is selected from -H and methyl.

5. (original) A compound selected from:

N-(4-{[[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide;

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-nitrobenzenesulfonamide;

4-Amino-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)propanamide;

N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-methylpropanamide;

N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(ethylamino)-*N*-methylbenzenesulfonamide;

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(formylamino)-*N*-methylbenzenesulfonamide;

N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide;

N^1-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N^2,N^2-dimethylglycinamide;

N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide;

N^1-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)glycinamide;

2-[(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate;

N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;

5-Bromo-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-chloro-*N*-methylpyridine-3-sulfonamide;

5-Bromo-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;

N-(5-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide;

N-(3-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

N^1-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N^2-(2-hydroxyethyl)glycinamide;

4-[(Aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-*N*-methylacetamide;

N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;

N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;

N^1-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N^2,N^2-dimethylglycinamide;

N^1-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)glycinamide;

N^1-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N^2-methylglycinamide;

N-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;

N-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-methoxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;

N-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-(formylamino)-*N*-methylpyridine-3-sulfonamide;

N-(5-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide;

N-[4-({[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

N-[4-({[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

N-(4-{[[2-*tert*-Butyl-1-(2-piperidin-1-ylethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

N-(4-{[[2-*tert*-Butyl-1-(1,4-dioxan-2-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

N-(4-{[{2-*tert*-Butyl-1-[(1-methylpiperidin-2-yl)methyl]-1*H*-benzimidazol-5-yl}(methyl)amino]sulfonyl}phenyl)acetamide;

N-(4-{[(2-*tert*-Butyl-1-{[(2*R*)-1-methylpiperidin-2-yl]methyl}-1*H*-benzimidazol-5-yl)(methyl)amino]sulfonyl}phenyl)acetamide;

N-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

4-Bromo-*N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-benzenesulfonamide;

N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-[(2-hydroxyethyl)amino]-*N*-methylbenzenesulfonamide;

N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(dimethylamino)-*N*-methylbenzenesulfonamide;

4-[bis(2-hydroxyethyl)amino]-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,4-dimethyl-3,4-dihydro-2*H*-1,4-benzoxazine-7-sulfonamide;

N-[4-({methyl[2-(1-methyl-1-pyridin-2-ylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

N-(4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino]sulfonyl}phenyl)acetamide;

4-[(aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;

N-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethyl-4-{[(methylamino)carbonyl]amino}benzenesulfonamide;

4-amino-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;

N-(4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;

2-[(4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate;

N-(4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;

N-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethyl-4-{[(isopropylamino)carbonyl]amino}benzenesulfonamide;

N-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

4-[(aminocarbonyl)amino]-*N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;

N-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-{[(methylamino)carbonyl]amino}benzenesulfonamide;

4-amino-*N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;

N-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]-2,2-dimethylpropanamide;

2-{[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate;

N-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]-2-hydroxyacetamide;

N-ethyl-4-{[(isopropylamino)carbonyl]amino}-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;

N-(4-{[[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

4-[(aminocarbonyl)amino]-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

2-Hydroxy-*N*-(4-{[[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

N-(4-{[[2-(1-ethoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

N-[4-({[1-(2-azetidin-1-ylethyl)-2-*tert*-butyl-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

3-[5-({[4-(acetylamino)phenyl]sulfonyl}amino)-2-*tert*-butyl-1*H*-benzimidazol-1-yl]propyl acetate;

N-{4-[({1-[(1*S*,4*S*)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-2-*tert*-butyl-1*H*-benzimidazol-5-yl}amino)sulfonyl]phenyl}acetamide;

N-[4-({[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-3-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;

N-{4-[({2-*tert*-butyl-1-[2-(tetrahydro-2*H*-pyran-4-yl)ethyl]-1*H*-benzimidazol-5-yl}amino)sulfonyl]phenyl}acetamide;

N-(4-{[[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;

4-[(aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

N-(4-{[[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;

N-(4-{[[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
N-(4-{[[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{[[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-3-methylbutanamide;
N-(4-{[[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-{[(isopropylamino)carbonyl]amino}-*N*-methylbenzenesulfonamide;
4-{Bis[(isopropylamino)carbonyl]amino}-*N*-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
N-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
4-[(aminocarbonyl)amino]-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
N-methyl-4-nitro-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
4-amino-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
2,2-dimethyl-*N*-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]propanamide;
2-{[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate;
4-{[(isopropylamino)carbonyl]amino}-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
2-Hydroxy-*N*-[4-({methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide
and pharmaceutically acceptable salts thereof.

6. (original) A compound of Formula IA, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



IA

wherein

G is CH or N;

X^1 is halogen;

R^1 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, $CH_3C(=O)$-O-, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, C_{3-5}heteroaryl, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^3 and $R^3{}_a$ are independently selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{1-3}alkyl-O-C(=O)-, C_{1-6}alkyl-HN-C(=O)-, H_2N-C(=O)-, and C_{1-6}acyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, C_{1-6}alkylamino, diC_{1-6}alkylamino, and C_{3-6}heterocycloalkyl; and

R^4 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, and C_{3-6}cycloalkyl-C_{1-4}alkyl.

7. (original) A compound as claimed in claim 6

wherein

G is CH or N;

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{4-6}cycloalkenyl-C_{1-4}alkyl and C_{3-6}heterocycloalkyl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{4-6}cycloalkenyl-C_{1-4}alkyl and C_{3-6}heterocycloalkyl-C_{1-4}alkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy, $CH_3C(=O)$-O-, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, and C_{4-6}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, and C_{4-6}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, C_{3-5}heteroaryl, methoxy, ethoxy and hydroxy;

R^3 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{1-3}alkyl-O-C(=O)-, C_{1-3}alkyl-HN-C(=O)-, H_2N-C(=O)-, and C_{1-6}acyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, methoxy, ethoxy, hydroxy, amino, methylamino, dimethylamino, and C_{3-6}heterocycloalkyl; and

R^4 is selected from –H and C_{1-3}alkyl.

8. (original) A compound as claimed in claim 6
wherein G is CH or N;

R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexanemethyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, tetrahydropyranyl-methyl, tetrahydropyranyl-ethyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdinyl-methyl;

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl,1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

R^3 is selected from –H, C_{1-6}alkyl, and C_{1-6}acyl, wherein said C_{1-6}alkyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected

from $CH_3C(=O)$-O-, halogen, methoxy, hydroxy, amino, methylamino, dimethylamino, pyrrolidinyl, piperidinyl and morpholinyl; and

R^4 is selected from –H and methyl.

9. (original) A compound as claimed in claim 6 wherein

G is CH or N;

X^1 is bromo;

R^1 is cyclohexyl-methyl, cyclobutyl-methyl, 4,4-difluorocyclohexanemethyl, N-methylpiperidine-2-yl methyl, and tetrahydropyranyl-methyl;

R^2 is t-butyl and 1,1-difluoroethyl;

R^3 is selected from –H, methyl, ethyl, propyl, 2-propyl, 2-hydroxyethyl, 2-methoxyethyl, formyl, acetyl, uriedo, N-isopropyl-ureido, ethylcarbonyl, 2-propylcarbonyl, t-butylcarbonyl, 2-amino-acetyl, 2-methylamino-acetyl, 2-dimethylamino-acetyl, 2-acetyloxy-acetyl, 2-hydroxy-acetyl, 2-bromo-acetyl, 2-(morpholin-1-yl)-acetyl, and 2-(pyrrolindin-1-yl)-acetyl; and

R^4 is selected from –H and methyl.

10. (original) A compound of Formula IB, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



IB

wherein

R^1 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro,

methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

"Het" is a nitrogen (as shown in Formula IB) containing heterocycle ring that is fused with phenyl ring "Ar," wherein "Het" is optionally substituted with one or more groups selected from C_{1-3}alkyl, halogen, cyano, methoxy, ethoxy, hydroxy, and amino; and

R^4 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, and C_{3-6}cycloalkyl-C_{1-4}alkyl.

11. (original) A compound as claimed in claim 10
wherein

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{4-6}cycloalkenyl-C_{1-4}alkyl and C_{3-6}heterocycloalkyl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{4-6}cycloalkenyl-C_{1-4}alkyl and C_{3-6}heterocycloalkyl-C_{1-4}alkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, and C_{4-6}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, and C_{4-6}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy and hydroxy;

"Het" is morpholinyl, wherein said morpholinyl is optionally substituted with one or more groups selected from C_{1-3}alkyl, halogen, cyano, methoxy, ethoxy, hydroxy, and amino; and

R^4 is selected from –H and C_{1-3}alkyl.

12. (original) A compound as claimed in claim 10
wherein R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexyl-methyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, tetrahydropyranyl-methyl, tetrahydropyranyl-ethyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdinyl-methyl;

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl,1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

"Het" is morpholinyl, wherein said morpholinyl is optionally substituted with one or more C_{1-3}alkyl; and

R^4 is selected from –H and methyl.

13. (original) A compound as claimed in claim 10
wherein

R^1 is cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexanemethyl, N-methylpiperidine-2-yl methyl, and tetrahydropyranyl-methyl;

R^2 is t-butyl and 1,1-difluoroethyl;

"Het" is morpholinyl, wherein said morpholinyl is optionally substituted with one or more C_{1-3}alkyl; and

R^4 is selected from –H and methyl.

14. (canceled)

15. (canceled)

16. (currently amended) A method for~~The use of a compound according to any one of claims 1-13 in the manufacture of a medicament~~ for the treatment of anxiety disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

17. (currently amended) ~~The use of a compound according to any one of claims 1-13 claim 1 in the manufacture of a medicament~~A method for the treatment of cancer, multiple sclerosis, Parkinson's disease, cancer, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

18. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1-13~~ claim 1 and a pharmaceutically acceptable carrier.

19. (currently amended) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to ~~any one of claims 1-13~~ claim 1.

20. (original) A method for preparing a compound of Formula I,



I

comprising:

reacting a compound of Formula II,



II

with a compound of R^2COX, in the presence of a base, such as an alkylamine, and optionally a coupling reagent, followed by treatment with an acid;

wherein

X is selected from Cl, Br, F and OH;

R^1 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^3 is selected from –H, C_{1-6}alkyl and C_{1-6}acyl optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, alkylamino, dialkylamino, and C_{3-6}heterocycloalkyl; and

R^4 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, and C_{3-6}cycloalkyl-C_{1-4}alkyl.

21. (original) A compound of 2-Bromo-*N*-(4-{[[2-tert-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide.

22. (original) A method for preparing a compound of Formula IA,



IA

comprising:

reacting a compound of Formula IIA,



IIA

with a compound of R^2COX, in the presence of a base, such as an alkylamine, and optionally a coupling reagent, followed by treatment with an acid;

wherein

X and X^1 are independently selected from Cl, Br, F and OH;

G is CH or N;

R^1 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, C_{4-8}cycloalkenyl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-10}cycloalkyl, C_{4-8}cycloalkenyl, and C_{3-6}heterocycloalkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, $CH_3C(=O)$-O-, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^2 is selected from C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl, wherein said C_{1-10}alkyl, C_{2-10}alkenyl, C_{3-10}cycloalkyl, C_{3-10}cycloalkyl-C_{1-4}alkyl, and C_{4-8}cycloalkenyl-C_{1-4}alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, C_{3-5}heteroaryl, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C_{1-6}alkylamino and diC_{1-6}alkylamino;

R^3 and $R^3{}_a$ are independently selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{1-3}alkyl-O-C(=O)-, C_{1-6}alkyl-HN-C(=O)-, H_2N-C(=O)-, and C_{1-6}acyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, and C_{1-6}acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)$-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, C_{1-6}alkylamino, diC_{1-6}alkylamino, and C_{3-6}heterocycloalkyl; and

R^4 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, and C_{3-6}cycloalkyl-C_{1-4}alkyl.

23. (New) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 2.

24. (New) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 3.

25. (New) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 4.

26. (New) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 5.

27. (New) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 6.